The Non-Malignant Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Sickle Cell Disease Channel on VJHemOnc is an independent medical education platform, supported with funding from Agios (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCAT 2023 | Disease-modifying and curative SCD treatment updates from ASCAT 2023
Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, provides her insights into therapeutic developments in sickle cell disease (SCD), an area currently experiencing significant progress. The research encompasses both disease-modifying strategies, such as using pyruvate kinase activators; and curative gene therapy options, with gene editing through CRISPR/Cas9 at the forefront. The field anticipates exciting advancements as therapies go under clinical review and await FDA approval. This interview was recorded at the 18th Annual Scientific Conference on Sickle Cell and Thalassemia (ASCAT) 2023, held in London, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
